亿帆医药：人生长激素注射液获药物临床试验批准

Core Viewpoint - Yifan Pharmaceutical (002019) has received approval from the National Medical Products Administration for clinical trials of its Human Somatropin Injection, a biosimilar to Novo Nordisk's recombinant human growth hormone [1] Group 1: Company Developments - Yifan Pharmaceutical's wholly-owned subsidiary, Yifan Pharmaceutical (Shanghai) Co., Ltd., has been granted a Clinical Trial Approval Notice for Human Somatropin Injection [1] - The drug is classified as a Class 3.3 therapeutic biological product under Chinese regulations [1] - Human Somatropin Injection is a biosimilar to Novo Nordisk's product (brand name: Norditropin) and shares the same amino acid sequence as natural human growth hormone [1] Group 2: Industry Context - Human Somatropin Injection is positioned as a mainstream therapy for growth hormone deficiency [1]